Adverse drug reactions of selected drugs and associations with transporter function
In many of these examples the involvement of additional transporters and other factors (e.g., drug metabolism) needs to be considered.
| Drug | Adverse Drug Reaction | Transporter | Reference |
|---|---|---|---|
| Adefovir | Nephrotoxicity | OAT1 | Ho et al., 2000; Servais et al., 2006 |
| Bosentan | Cholestatic liver injury | BSEP | Fattinger et al., 2001 |
| Cidofovir | Nephrotoxicity | OAT1 | Ho et al., 2000 |
| Cisplatin | Nephrotoxicity | OCT2 | Filipski et al., 2009; Ciarimboli et al., 2010 |
| Cyclosporine | Cholestatic liver injury | BSEP | Byrne et al., 2002 |
| Nephrotoxicity | P-gp | Zolk and Fromm, 2011 | |
| Glibenclamide | Cholestatic liver injury | BSEP | Byrne et al., 2002 |
| Irinotecan | Diarrhea | MRP2 | de Jong et al., 2007 |
| Myelosuppression | BCRP | Cha et al., 2009 | |
| Loperamide | Respiratory depression | P-gp | Sadeque et al., 2000 |
| Metformin | Hyperlactatacidemia, lactic acidosis | Organic cation transporters | Zolk, 2012 |
| Methotrexate | Nephrotoxicity | MRP2 | Hulot et al., 2005; Vlaming et al., 2009 |
| Mycophenolate mofetil | Leucopenia, anemia, thrombocytopenia, diarrhea, nausea, vomiting, infection | OATP1B1 | Michelon et al., 2010 |
| Rifampin | Cholestatic liver injury | BSEP | Byrne et al., 2002 |
| Simvastatin | Myopathy | OATP1B1 | Link et al., 2008; Voora et al., 2009; Brunham et al., 2012 |
| Tacrolimus | Nephrotoxicity | P-gp | Zolk and Fromm, 2011 |
| Tenofovir | Nephrotoxicity | OAT1 | Ray et al., 2006 |
| Troglitazone | Cholestatic liver injury | BSEP | Funk et al., 2001 |